Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.

Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W, Holodny AI, Omuro AM.

Neurology. 2011 May 31;76(22):1918-24. doi: 10.1212/WNL.0b013e31821d74e7.

2.

Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.

Baek HJ, Kim HS, Kim N, Choi YJ, Kim YJ.

Radiology. 2012 Sep;264(3):834-43. doi: 10.1148/radiol.12112120. Epub 2012 Jul 6.

PMID:
22771885
3.

Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.

Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER.

Oncologist. 2014 Jan;19(1):75-81. doi: 10.1634/theoncologist.2013-0101. Epub 2013 Dec 5.

4.

Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Galldiks N, Dunkl V, Stoffels G, Hutterer M, Rapp M, Sabel M, Reifenberger G, Kebir S, Dorn F, Blau T, Herrlinger U, Hau P, Ruge MI, Kocher M, Goldbrunner R, Fink GR, Drzezga A, Schmidt M, Langen KJ.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):685-95. doi: 10.1007/s00259-014-2959-4. Epub 2014 Nov 20.

PMID:
25411133
5.

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M.

J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163.

6.

Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.

Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B.

Am J Clin Oncol. 2012 Jun;35(3):284-9. doi: 10.1097/COC.0b013e318210f54a.

PMID:
21399487
7.

Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.

Agarwal A, Kumar S, Narang J, Schultz L, Mikkelsen T, Wang S, Siddiqui S, Poptani H, Jain R.

J Neurooncol. 2013 May;112(3):413-20. doi: 10.1007/s11060-013-1070-1. Epub 2013 Feb 18.

PMID:
23417357
8.

[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].

Lichy MP, Bachert P, Hamprecht F, Weber MA, Debus J, Schulz-Ertner D, Schlemmer HP, Kauczor HU.

Rofo. 2006 Jun;178(6):627-33. Epub 2006 May 15. German.

PMID:
16703499
9.

Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.

Laprie A, Catalaa I, Cassol E, McKnight TR, Berchery D, Marre D, Bachaud JM, Berry I, Moyal EC.

Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):773-81. doi: 10.1016/j.ijrobp.2007.10.039.

PMID:
18262090
10.

Pseudoprogression and treatment effect.

Jahangiri A, Aghi MK.

Neurosurg Clin N Am. 2012 Apr;23(2):277-87, viii-ix. doi: 10.1016/j.nec.2012.01.002. Epub 2012 Feb 14. Review.

PMID:
22440871
11.

Proton magnetic resonance spectroscopy and diffusion-weighted imaging in intracranial cystic mass lesions.

Lai PH, Hsu SS, Ding SW, Ko CW, Fu JH, Weng MJ, Yeh LR, Wu MT, Liang HL, Chen CK, Pan HB.

Surg Neurol. 2007;68 Suppl 1:S25-36.

PMID:
17963918
12.

High levels of cellular proliferation predict pseudoprogression in glioblastoma patients.

Pouleau HB, Sadeghi N, Balériaux D, Mélot C, De Witte O, Lefranc F.

Int J Oncol. 2012 Apr;40(4):923-8. doi: 10.3892/ijo.2011.1260. Epub 2011 Nov 11.

13.

[Prediction of clinical course of glioblastomas by MRI during radiotherapy].

Leitzen C, Schild HH, Bungart B, Herrlinger U, Lütter C, Müdder T, Wilhelm-Buchstab T, Schüller H.

Strahlenther Onkol. 2010 Dec;186(12):681-6. doi: 10.1007/s00066-010-2156-8. Epub 2010 Nov 29. German.

PMID:
21221885
14.

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

Roldán GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC.

Can J Neurol Sci. 2009 Sep;36(5):617-22.

PMID:
19831132
15.

Glioblastoma multiforme versus solitary supratentorial brain metastasis: differentiation based on morphology and magnetic resonance signal characteristics.

Maurer MH, Synowitz M, Badakshi H, Lohkamp LN, Wüstefeld J, Schäfer ML, Wiener E.

Rofo. 2013 Mar;185(3):235-40. doi: 10.1055/s-0032-1330318. Epub 2012 Nov 29.

16.

Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

Fabi A, Russillo M, Metro G, Vidiri A, Di Giovanni S, Cognetti F.

Anticancer Res. 2009 Jul;29(7):2607-10.

17.

[Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].

Cai L, Gao S, Li DC, Li YS, Chen QS, Xing XL.

Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):134-8. Chinese.

PMID:
19538892
18.

Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.

Radbruch A, Fladt J, Kickingereder P, Wiestler B, Nowosielski M, Bäumer P, Schlemmer HP, Wick A, Heiland S, Wick W, Bendszus M.

Neuro Oncol. 2015 Jan;17(1):151-9. doi: 10.1093/neuonc/nou129. Epub 2014 Jul 18.

19.

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.

Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S, Suput D, Demaerel P.

Neuroradiology. 2011 Oct;53(10):721-31. doi: 10.1007/s00234-010-0802-6. Epub 2010 Nov 25.

PMID:
21107549
20.

Imaging after GliaSite brachytherapy: prognostic MRI indicators of disease control and recurrence.

Kleinberg L, Yoon G, Weingart JD, Parisi M, Olivi A, Detorie NA, Chan TA.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1385-91. doi: 10.1016/j.ijrobp.2008.12.074. Epub 2009 Apr 23.

PMID:
19394153
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk